Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research · New York Stock Exchange
InsiderStreet
EQUITY FACTSHEET
Generated: 2026-Oct-18 · Market data through: 2026-10-16
Last Close
$436.95
2026-10-16
Market Cap
$42.9B
Volume
0.9M
52-Wk High
$454.54
52-Wk Low
$282.77
Trailing PE
108.7
P/S
9.24
Gross Margin
50.8%
Net Margin
3.6%
ROE
2%
ROIC
1%
Piotroski
5/9
Altman Z
3.6
1-Yr Return
+30.5%
5-Yr Return
+110.6%
Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.
SectorHealthcareIndustryMedical - Diagnostics & ResearchExchangeNYSEMarket Cap$42.9BEmployees7,900 (SEC-filed)CEOUdit BatraIPO1995-11-17CountryUS
34 Maple Street, Milford, MA 01757  ·  Tel 508 478 2000  ·  waters.com
INSIDERSTREET SCORE47 / 100Street mean $461.82 (11 analysts, last qtr) — their number, not ours
INSIDER CONSENSUS SIGNALTWO-WAY FLOW$0.5M buys against $1.4M sells / 6 mo
1 Year vs S&P 500 · WAT +30.5% · S&P 500 +15.9% · spread +14.6pp
82100118136Sep 25Nov 25Jan 26Mar 26May 26Jul 26Aug 26WATS&P 500
7 Years vs S&P 500 · WAT +110.6% · S&P 500 +189.9% · spread -79.3pp
671472263062019202020212023202420252026WATS&P 500
Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.
This space intentionally left blank — the next section begins on the following page

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
INSIDERSTREET
SCORE
47of 100

Score Breakdown

Profitability16/100
Growth40/100
Momentum70/100
Quality60/100
Earnings Quality70/100
Balance Sheet44/100
Value35/100
Risk (safety)80/100
Overall46.5/100
Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

SymbolIS Score
IQV
56
IDXX
80
ILMN
58
A
71
MTD
63
NTRA
50
WAT
47

IS Score Trend — quarterly

3345566823 Q123 Q324 Q124 Q325 Q125 Q326 Q1
14 quarters, 23 Q1 to 26 Q2. Peak 66 in 24 Q4, latest 47 — -20 since. Dropped below the 55 line in 26 Q1, at 35. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.
BUSINESS QUALITY47 / 100IS Score 46.5 / 100 · -19.8 from peak of 66
3345566823 Q123 Q424 Q325 Q226 Q1
Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.
PRICE STRUCTUREBULLISHTechnical Score 77 / 100 · Power +54 · 18 of 22 indicator votes bullish
32%56%80%104%07-2308-1309-0309-2510-16
Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 47, price structure 77 out of 100, so the price reads better than the business does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

TriggerWhere it stands nowWhat it would mean
IS Score reaches 55 and holds two consecutive quartersnow 46.5would move us up one band
IS Score stops falling - one quarter higher than the priorlast four: 64 → 61 → 35 → 47the direction matters more than the level
Technical vote share back above 50%now 64%price structure no longer broken
Institutional holder count rises two quarters runningpeak 1,189 → now 1,189fewer institutions willing to hold is our clearest warning
We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score2 of 4top 13% of 29,420 symbols
Sources Aligned— of 3independent disclosures
Congress (180d)0 buysnone disclosed
Insider Buys (180d)0none disclosed
ETF Funds (30d)1179 up / 1014 downnet +165 funds
Institutions Added (13F)10managers opening or increasing
Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

621821102112212023 Q32024 Q12024 Q32025 Q12025 Q32026 Q1
Peak 1,189 · latest 1,189 (+0 from peak).
QuarterHolders13F sharesValueReported own%Guard
2026 Q21,18998.8M$35.1B100.6%ex-outlier 92.0%
2026 Q11,17994.9M$27.2B96.6%
2025 Q481057.7M$21.4B58.7%
2025 Q375757.3M$17.0B58.4%
2025 Q277358.4M$20.3B59.5%
2025 Q176657.7M$21.1B58.8%
2024 Q476457.2M$21.0B58.2%
2024 Q369756.5M$20.0B57.6%
2024 Q269656.9M$16.3B58.0%
2024 Q169458.5M$20.1B59.6%
2023 Q467959.1M$19.2B60.1%
2023 Q365357.3M$15.7B58.3%
How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

Why 2026-06 reads 100.60%. Institutions cannot hold more of a company than exists. The reported 98.8M shares exceed the 98.2M outstanding, and a single filer accounts for the excess: BlackRock, Inc. reports 8,484,939 shares against 8,543,014 the prior quarter, a 1x jump, which alone would be 8.6% of the company. Excluding that filing, ownership is 92.0%. We publish both figures. 13F filings are due 45 days after quarter end and amendments keep arriving after that, so the newest quarter is provisional by construction - this is what an unsettled quarter looks like.

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
InsiderRoleDateTypeSharesValuePost-Txn Owned
Knight Heatherdirector2026-09-30A-Award57—1,338
Jiang Weidirector2026-09-30A-Award57—3,630
Kuebler Christopher Adirector2026-08-06EXERCISE3,626$0.49M21,434
Kuebler Christopher Adirector2026-08-06SELL3,626$1.44M17,808
Kuebler Christopher Adirector2026-08-06EXERCISE3,626$0.49M0
Knight Heatherdirector2026-06-30A-Award63—1,281
Jiang Weidirector2026-06-30A-Award67—3,573
Carpio Robert L IiiSVP Waters Analytical Sciences2026-06-24TAX W/H189$0.07M3,426
6-mo decomposition (Form 4)TxnsSharesValueSignal weight
S — Open-market sales13,626$1.4MCounted
P — Open-market purchases21,500$0.5MCounted
M — Exercises (paired A/D)13,626$0.5MNone — mechanics
F — Tax withholding65,266$1.6MNone — compensation

Monthly Net Insider Flow (000 shares)

-4K-2K-1K0K-303-004-005-006-408+009
Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalTwo-Way Flow
Open-Market Sells$1.4M1 txns / 6 mo
Open-Market Buys$0.5M2 txns / 6 mo
ClusterNone active3+ insiders / 21 days
FiledFilerShares registeredEst. proceeds
2026-08-06Kuebler Christopher A3,626$1.4M
2024-05-15Kuebler Christopher A4,000$1.4M
2024-03-13Baddour Linda500$0.2M
2023-12-15Pratt Jonathan M2,116$0.7M
Trailing 12 mo1 filings3,626$1M
FiledFormReporting person% of classShares
2026-05-15SCHEDULE 13G/AFundsmith LLP4.40%4.3M sh
2026-04-30SCHEDULE 13GVanguard Capital Management7.49%7.4M sh
2026-04-24SCHEDULE 13G/ABlackRock, Inc.7.80%7.6M sh
2026-03-27SCHEDULE 13G/AThe Vanguard Group—exit/reporting change

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
MemberChamberTradeSize bandTradedDisclosed
Kevin HernHouseSELL$1,001 - $15,0002026-08-132026-09-02
Kevin HernHouseSELL$1,001 - $15,0002026-08-132026-09-02
Kevin HernHouseSELL$1,001 - $15,0002026-08-122026-09-02
Tommy TubervilleSenateSELL$1,001 - $15,0002024-05-032024-06-14
Tommy TubervilleSenateSELL$1,001 - $15,0002024-05-032024-06-13
Thomas Hawley TubervilleSenateSELL$1,001 - $15,0002024-05-032024-06-13
House 12-Mo24 trades9 purchases
Senate 12-Mo0 tradesNone purchases
CoverageSTOCK Act filings30-45 day disclosure lag
13F Filers (last complete Q)1,179
13F Shares95M96.6% of shares out
New / Closed466 / 82positions, QoQ
Increased / Reduced577 / 108positions, QoQ
Put/Call (13F)0.90option positions
Free Float99.9%98M sh

2.8 · Largest Reporting 13F Managers

ManagerSharesValue
Assenagon Asset Management S.A.140,202$62M
Schaper Benz & Wise Investment Cou102,776$45M
Fjarde Ap-Fonden /Fourth Swedish N33,877$15M
Mn Services Vermogensbeheer B.V.28,659$13M
Czech National Bank28,229$12M
Td Waterhouse Canada Inc.25,135$11M
EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

FundWeightPosition
VITSX0.1%$1.4B
VTI0.1%$1.4B
VTSAX0.1%$1.4B
VSMPX0.1%$1.4B
VFIAX0.1%$1.1B
VOO0.1%$1.1B

13F Filers Holding WAT — quarterly

6648491034121924Q124Q325Q125Q326Q1

Institutional Put/Call — quarterly

0.690.951.211.4724Q124Q325Q125Q326Q1
This space intentionally left blank — the next section begins on the following page

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
31%49%66%84%07-2308-1008-2609-1409-30
Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.
Latest Session61.5%2026-10-15
20-Day Avg56.5%50-day 59.7%
TrendFalling20d vs 50d
By Market CenterQ: 60% · N: 92% · B: 69%latest session
Weekly Notional ($B)
$0.3B$0.5B$0.7B$1.0B06-1507-0607-2708-17

Where WAT Trades in the Dark

ATS Venue (4-wk)SharesAvg trade
Incr Intelligent Cross Llc2.0M34 sh
Sgmt Sigma X21.2M33 sh
Mlix Instinct X0.9M52 sh
Ebxl Level Ats0.9M25 sh
Mstx Ms Trajectory Cross (Ats-1)0.7M25 sh
Mspl Ms Pool (Ats-4)0.7M78 sh
Waters Instrument Syst$1.1BWaters Service$1.1BChemistry Consumables$0.6BTa Instrument Systems$0.2BTa Service$0.1BRevenue$3.2BGross profit$1.8BCost of revenue$1.3BOperating income$0.9BR&D$0.2BSG&A$0.7BNet income$0.6BTax$0.1B
Where a dollar of Waters Corporation revenue goes. All values FY2025 filings, live.
RegionRevenueShare
Americas$1.2B37%
Asia Pacific$1.0B33%
Europe$963M30%

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
SwitchingIntangiblesNetworkCost adv.Scale
WAT (live moat model)Peer median: IQV · IDXX · ILMN · A · MTD
Component scores from the live moat model. Peer median illustrative.

Moat score 34/100 — None; primary source Efficient Scale.

3.8 · Employees (SEC filings)

7K8K8K8K2018202020222024
OfficerTitle
Udit BatraPresident, Chief Executive Officer & Director
Amol ChaubalSenior Vice President & Chief Financial Officer
Robert L. CarpioSenior Vice President of Waters Analytical Sciences
Jianqing Y. BennettSenior Vice President of Waters Advanced Diagnostics Division
Revenue ($B)
$0B$2B$5B$7B3FY213FY223FY233FY243FY256FY26E7FY27E
EPS ($) — GAAP diluted actual, street-basis estimate
$0.00$5.50$10.99$16.4911.17FY2111.73FY2210.84FY2310.71FY2410.76FY2514.58FY26E16.49FY27E
Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
Quarterly EPS — Actual vs. Consensus
$0.00$1.81$3.62$5.4425-0525-0825-1126-0226-0526-08NextE
Beats (>2%)2 of 6recent quarters
Avg Surprise+4.4%
Next Report2026-11-03
Income Quality3.31OCF ÷ net income
Beat Rate—%0 of 0 quarters
Current Streak0longest 0
Avg EPS Surprise—%median —%
Surprise Trend—last 4 vs prior 4
PeriodEPS est.EPS actualEPS surpriseRev est. ($M)Rev actual ($M)Rev surprise
Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.
$0B$1B$2B$3BFY21FY22FY23FY24FY25RevenueGross profitOperating incomeNet income
Profit Margins (%)
0%20%40%60%58.529.524.9FY2158.029.423.8FY2259.627.721.7FY2359.427.921.6FY2457.828.220.3FY25GrossOperatingNet

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
Revenue by Segment — Stacked
$0B$1B$2B$3B$3BFY21$3BFY22$3BFY23$3BFY24$3BFY25Waters InstrumWaters ServiceChemistry ConsTa Instrument Ta Service
Live segmentation data.
YoY Growth Heatmap — Income Lines
YoY growthFY21FY22FY23FY24FY25
Revenue+17.8%+6.7%-0.5%+0.1%+7.0%
Gross profit+19.9%+5.8%+2.2%-0.2%+4.0%
Operating income+27.3%+6.3%-6.4%+1.1%+8.1%
Net income+32.8%+2.2%-9.3%-0.7%+0.8%
$B · FY endsFY21FY22FY23FY24FY25Trend
Revenue2.83.03.03.03.2
Cost of revenue1.21.21.21.21.3
Gross profit1.61.71.81.81.8
R&D expense0.20.20.20.20.2
SG&A expense0.60.70.70.70.7
Operating income0.80.90.80.80.9
EBITDA1.01.01.01.01.0
D&A0.10.10.20.20.2
Pretax income0.80.80.70.80.8
Income tax0.10.10.10.10.1
Net income0.70.70.60.60.6
Diluted EPS ($)11.1711.7310.8410.7110.76
Diluted shares (M)6260596060
Operating CF$1B
CapEx$0B
Free cash flow$1B
SBC$0B
Buybacks$0B
Net cash change$0B

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
Operating cash flow$0.65BFree cash flow$0.54BCapEx$0.11BBuybacks$0.01BRetained cash$0.53B

Balance Sheet — Full

$BFY22FY23FY24FY25
Cash & equivalents0.50.40.30.6
ST investments0.00.00.00.0
Receivables (net)0.70.70.70.8
Total current assets1.81.81.72.0
PP&E (net)0.70.70.70.6
Goodwill + intangibles0.71.91.91.9
Total assets3.34.64.65.1
Accounts payable0.10.10.10.0
Short-term debt0.10.10.00.0
Deferred revenue0.20.30.30.0
Total current liabilities0.80.80.80.0
Long-term debt1.52.31.61.4
Total liabilities2.83.52.72.5
Shareholders' equity0.51.21.82.6

Cash Flow Statement — Full

$BFY22FY23FY24FY25
Net income0.70.60.60.6
D&A0.10.20.20.2
Stock-based compensation0.00.00.00.1
Working capital change(0.3)(0.2)(0.1)(0.3)
Operating cash flow0.60.60.80.7
Capital expenditures(0.2)(0.2)(0.1)(0.1)
Investing cash flow(0.1)(1.4)(0.1)(0.2)
Buybacks(0.6)(0.1)(0.0)(0.0)
Dividends paid0.00.00.00.0
Debt issuance / (repay)0.10.8(0.7)(0.2)
Financing cash flow(0.5)0.8(0.7)(0.2)
Free cash flow0.40.40.60.5
This space intentionally left blank — the next section begins on the following page

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
Balance Sheet Structure ($B)
$0B$2B$3B$5BFY22FY23FY24FY25Total assetsTotal liabilitiesEquity
Cash Generation vs Capex ($B)
$0B$0B$1B$1BFY22FY23FY24FY25Operating CFCapexFree cash flow
Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.
RatioFY21FY22FY23FY24FY25TTMTrend
PROFITABILITY
ROE231.1%162.3%77.6%42.8%29.3%2%
ROA23.3%22.2%16.2%13.9%13.3%0.7%
ROIC50.5%43.7%22.3%21.8%21.2%1.3%
Gross margin58.5%58.0%59.6%59.4%57.8%50.8%
Operating margin29.5%29.4%27.7%27.9%28.2%8.0%
Net margin24.9%23.8%21.7%21.6%20.3%3.6%
EBITDA margin35.3%34.2%33.9%35.0%32.0%20.5%
FCF margin20.8%14.7%15.0%20.9%17.1%—
VALUATION
P/E33.0328.8730.4034.6935.32108.7
P/B62.2740.5016.9712.108.862.8
P/S8.226.886.607.487.179.24
P/FCF39.5346.8644.1635.7142.05107.7
EV/EBITDA24.3421.2521.5522.6822.9550.1
EV/Revenue8.597.277.307.947.4310.3
Earnings yield3.0%3.5%3.3%2.9%2.8%0.39%
FCF yield2.5%2.1%2.3%2.8%2.4%0.93%
RatioFY21FY22FY23FY24FY25TTMTrend
LEVERAGE & SOLVENCY
Current ratio2.392.242.222.11—1.86
Quick ratio1.871.661.571.51—1.29
Debt / equity4.363.302.120.930.550.35
Debt / assets51.7%50.7%52.8%37.4%27.7%21.2%
Net debt / EBITDA1.051.162.041.330.804.96
Interest coverage18.9418.178.459.4212.82—

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
RatioFY21FY22FY23FY24FY25TTMTrend
EFFICIENCY
Asset turnover0.940.930.750.640.660.19
Receivables turnover4.704.454.154.124.052.3
DSO (days)7882888990156
DPO (days)2728272814138
Cash conversion cycle155173209212223238
GROWTH (YoY)
Revenue growth17.8%6.7%-0.5%0.1%7.0%—
Net income growth32.8%2.2%-9.3%-0.7%0.8%—
EPS growth35.2%5.2%-8.7%-1.2%0.6%—
FCF growth-6.3%-24.7%1.4%40.1%-12.9%—
PER SHARE ($)
EPS (diluted, TTM)11.2811.8710.8310.6910.751.69
Book value / share5.988.4619.4030.6642.86154.73
Revenue / share45.3649.8349.8549.6052.9647.29
FCF / share9.437.317.4610.399.034.06
Cash / share9.278.076.685.459.845.49
SHAREHOLDER RETURN & SCORES
Buyback yield2.8%3.1%0.4%0.1%0.1%0.04%
Altman Z-Score10.7410.207.629.377.023.6
Piotroski F-Score764655/9
Beneish M-Score-2.52-2.19-2.08-2.54-2.34-0.61
ModelScoreZoneNote
Piotroski F-Score5 / 9Middling
Altman Z-Score3.6Safe (>2.99)Safe
Income quality3.31Cash-backedOCF ÷ net income
Beneish M-Score-0.61Elevatedvs −2.22 threshold
DuPont Decomposition (TTM)Value
Tax burden0.81
Interest burden0.61
Operating margin7.3%
Asset turnover0.32×
Financial leverage1.70×
= ROE2%
Growth Quality (live)Value
Revenue stability0.56
Earnings stability0.49
Earnings persistence0.50
Revenue CAGR 3y15.8%
EPS CAGR 3y-47.1%
FCF CAGR 3y1.0%
This space intentionally left blank — the next section begins on the following page

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
Buyback Yield0.04%
Dividend Yield0.00%
Total Shareholder Return-0.02%cash yield
SBC / Revenue1.6%dilution pressure
P/E · now 108.722x53x84x115x
P/S · now 9.246.4x7.4x8.4x9.4x
EV/EBITDA · now 50.119x30x41x52x
CompanyMkt capP/EROENet marginRev growthPiotroski1-yr ret
IQV$43.9B32.823%5.9%+8.2%7/9+29.8%
IDXX$44.1B39.474%27.8%+12.8%9/9-12.1%
ILMN$39.6B48.532%17.9%+4.9%7/9+173.7%
A$48.8B34.021%19.3%+8.6%7/9+22.6%
MTD$32.5B36.4-736%22.7%+6.9%8/9—
NTRA$56.7B-289.3-13%-8.9%+37.8%6/9—
DGX$25.9B24.614%10.5%+9.9%8/9—
LH$25.8B26.112%8.0%+6.4%8/9—
1-yr returns computed from adjusted price history; peers without a tracked series show —.
Buy
37 Analysts
Str Sell (0)Sell (2)Hold (16)Buy (19)Str Buy (0)
Mean Target (qtr)$461.8211 targets
Target vs. Price+5.7%last-quarter mean
Next Report2026-11-03street $4.00
Consensus estimatesRevenue meanHigh / LowEPS meanHigh / Low# EPS est.
FY2026$6.46B$6.48B / $6.45B$14.58$14.63 / $14.5212
FY2027$7.13B$7.30B / $7.04B$16.49$17.73 / $15.9514
FY2028$7.55B$7.96B / $7.40B$18.41$22.39 / $14.705

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

WindowAvg Targetvs. Price# Targets
Last Month$501.67+14.8%3
Last Quarter$461.82+5.7%11
Last Year$425.97-2.5%29
All Time$404.29-7.5%45
Rolling mean of published targets vs. last close $436.95. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B-
DCF
3/5
ROE
2/5
ROA
4/5
Debt/Eq
2/5
P/E
1/5
P/B
3/5
Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.
WAT +30.5% vs S&P 500 +15.9% — spread +14.6pp
82100118136Sep 25Nov 25Jan 26Mar 26May 26Jul 26Aug 26WAT +31%S&P 500 +16%
Sector — XLV +24.2%
82100118136Sep 25Nov 25Jan 26Mar 26May 26Jul 26Aug 26WATXLV
Peer Set — indexed to 100
64142220298Sep 25Nov 25Jan 26Mar 26May 26Jul 26Aug 26WAT +31%IQV +30%IDXX -12%ILMN +174%A +23%
All series indexed to 100 at the start of the window, adjusted closes.

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
$279$340$400$4603MVol705030RSI 56Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26▮ up▮ downSMA20SMA50BB(20,2)RSI(14)
Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.
$278$335$392$449Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26▮up▮downSMA 20SMA 50SMA 200EMA 9EMA 21·· ST Bull·· ST Bear
Moving AverageValueDistance% DistanceSignal
SMA 20$433.25+3.70+0.85%Above
SMA 50$420.53+16.42+3.90%Above
SMA 200$366.23+70.72+19.31%Above
EMA 9$435.55+1.40+0.32%Above
EMA 21$431.15+5.80+1.35%Above
EMA 50$418.46+18.49+4.42%Above
EMA 200$379.26+57.69+15.21%Above
Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
TECHNICAL VERDICTBULLISHPower Score +5418 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%90
Momentum 25%80
Volume 20%81
Volatility 10%83
Patterns 15%38
32%56%80%104%07-2308-1309-0309-2510-16
This Week64% bullishof 11 price-based votes
4 Weeks Ago100%-36 pts since
12 Weeks Ago100%-36 pts since
ReadDeterioratingweek-over-week trajectory
Price vs SMA 20$433.25
Price vs SMA 50$420.53
Price vs SMA 200$366.23
EMA 9/21 Cross435.6/431.1
SMA 50/200Golden
ADX DirectionADX 29
Supertrend$409
Parabolic SAR$451
SMA Slope0.770
RSI55.9
Stochastic K/D54/47
StochRSI K/D36/26
Williams %R-53
CCI87
TSI vs Signal14.9
CMO11.8
ROC2.78%
OBV SignalDistrib
Chaikin MF0.020
MFI52
Force Index1M
Elder Ray Bull17.24
55.9RSI (14)30 oversold · 70 overbought
53.6Stochastic %Kvs %D 47
51.9Money Flowvolume-weighted RSI
29.3ADXtrend strength · <20 weak
53.2Williams %Rinverted scale
LevelValueLevelValue
Pivot / R1 / R2$443.02 / $450.25 / $456.35S1 / S2$436.92 / $429.69
Bollinger (20,2)$419.73 – $446.76SqueezeON
52-wk range$282.77 – $454.54Off 52-wk high-3.9%
ATR (14)$12.68 (2.9%)Historical vol25.3%

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
+1.5%Jan50%
-1.3%Feb45%
+0.8%Mar62%
+0.3%Apr50%
+0.3%May55%
+1.8%Jun65%
+1.3%Jul50%
-1.1%Aug55%
+0.1%Sep55%
+1.7%Oct60%
+2.6%Nov70%
+0.5%Dec50%
Sample: 20 years — treat short histories as suggestive, not statistical.
Computed from live weekly pricesWATS&P 500
Weekly volatility (σ, 1y)4.91%1.83%
Best / worst week (1y)+15.6% / -14.3%—
Max drawdown (5y, monthly)-37.4%—
1-week VaR (95%)-8.5%—
Beta (5y)1.191.00
WAT EQUITY WEATHER (LIVE)PARTLY CLOUDY · +17
Trend+42
Momentum+15
Volume+39
Volatility-30
Breadth-30
MARKET REGIME (2026-10-16)NEUTRAL
VIX19.99Normal
Dow TheoryConfirmed Bearish
SPY / QQQ TSI7.2 / 4.7trend strength
Sector Strength46/100breadth average
-1.01-0.34+0.34+1.0102-0203-0904-2006-0108-0309-14
Average sentiment of 99 stories, weekly buckets, −1 to +1.
This space intentionally left blank — the next section begins on the following page

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY
Overall+16.8+33.8 vs industry
Trend+42.5+49.7 vs industry
Momentum+15.2+42.2 vs industry
Volume+38.8+38.8 vs industry
ReadingWATMedical - Diagnostics & Research
n=227
Healthcare
n=5,272
All US symbols
n=70,435
Overall+16.8-17.0-24.0-20.5
Trend+42.5-7.2-25.6-21.3
Momentum+15.2-27.0-28.5-15.8
Volume+38.8+0.0-25.0-3.8
Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.
ExecutiveTotal compStructure
Udit Batra, Ph.D., President & CEO$14.0M70% equity+incentive
Amol Chaubal, SVP & CFO$3.8M65% equity+incentive
Jianqing Y. Bennett, SVP, TA & Clinical Divi$3.0M61% equity+incentive
Robert Carpio III, SVP, Waters Division$2.8M62% equity+incentive
Pillar (live disclosure scores)Score
Environmental64
Social67
Governance78
Composite ESG70
Composite ESG Trend
6869707120172019202120232025
Filed8-K contentsItems
2026-08-21Officer/Director Change; Other Events5.02,8.01
2026-08-04Earnings Release; Exhibits2.02,9.01
2026-05-22Shareholder Vote5.07
2026-05-05Earnings Release; Exhibits2.02,9.01
2026-03-23Material Agreement; Financial Obligation; Other Events; Exhibits1.01,2.03,8.01,9.01
2026-03-16Other Events; Financial Statements and Exhibits8.01,9.01
2026-02-09Results of Operations and Financial Condition; Financial Statements an2.02,9.01
2026-02-09Entry into Material Definitive Agreement; Completion of Acquisition or1.01,2.01,2.03,5.02,7.01,9.01

Waters Corporation (WAT)

Healthcare / Medical - Diagnostics & Research
InsiderStreet
EQUITY FACTSHEET
Report Date: 2026-Oct-18
NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.
Data domainSourceCoverage for this report
Price & volumemarket_db.historical_prices52 rows
Fundamentalsincome_statements_annual6 rows · 2020 to 2025
Reported vs consensusfact/earnings_calendar24 rows · 2020-10-27 to 2026-08-04
Analyst estimatesdim/forward_estimates3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)holdings_db.institutional_ownership_summary114 rows · 1998 to 2026
Insider transactions (Form 4)edgar/form412 rows · 2026-03-31 to 2026-09-30
Proposed sales (Form 144)edgar/form1441 record
Beneficial ownership (13D/G)edgar/13dg4 rows · 2026-03-27 to 2026-05-15
Short-sale volume (FINRA)edgar/short_volume_daily60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)edgar/darkpool_weekly12 rows · 2026-06-15 to 2026-08-31
ETF & fund holdingetf_holdings_changelog (30d)1 record
Peer setstock_peers_dynamic8 rows
Industry mediansindustry_medians1 record
Congressional tradescongress_db (House + Senate)1 record
ESGfact/esg_disclosures1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.